Developer docs
API playgroundTry for free, no card

Search company profiles

AsedaSciences

Full company profile

uuid00096mi

Namestring
AsedaSciences
Legal namestring
AsedaSciences AG
Company typeenum
Private
Founded yearint
2012
Descriptiontext

AsedaSciences operates the 3RnD platform, a cloud-based, AI-driven ecosystem that combines machine learning with proprietary high-content cellular screening to predict human toxicity risk and support the design of safer chemical and pharmaceutical compounds. The platform is built around the generation of standardized biological fingerprints using SYSTEMETRIC flow-cytometry-based multiparametric screens (12 cellular stress parameters across 10 concentrations), with proprietary ML algorithms comparing new compound fingerprints against a library of 3,000+ historical fingerprints to generate a Cell Health Index risk score. Native integration with 3RnD also covers complementary screening modalities including ZBEScreen zebrafish screening (16 organ and behavioral endpoints via partnership with Tanguay Lab), Biomimetic Chromatography (Valko Screen, 6 endpoints developed with Dr. Klara Valko), compound QC, and a Kinome profiling module; visualization layers include Compound Universe, Zebrafish Universe, and Kinome Universe, with add-on tools such as the SciScore NLP engine (scoring research rigor across 2.2M+ publications) and GOSTAR compound reports from Excelra.

The company monetizes through four streams: SaaS subscriptions to the 3RnD platform on tiered monthly plans ranging from a free entry tier through a $299/month commercial tier; pay-as-you-go contract screening services priced $180-$2,000 per test depending on assay complexity; enterprise software licensing for SciScore and specialized tools; and premium access to proprietary datasets including the 3,000+ compound biological fingerprint database. Go-to-market is hybrid: a product-led freemium motion at the individual researcher level, direct enterprise field sales targeting pharma and biotech for full-service screening contracts, and regional channel partners (e.g., Chayon Laboratories for South Korea). Customer segments span pharmaceutical and biotechnology companies (primary), agricultural chemicals, industrial chemicals, cosmetics, food safety, and academic drug discovery groups across 186 countries.

The company is incorporated as AsedaSciences AG in Schindellegi, Switzerland (global headquarters) and AsedaSciences Inc. in West Lafayette, Indiana (US operations and laboratory facilities). Operative leadership is led by co-founder and CEO Brad Calvin, who previously held executive roles at Abbott, Digene, Beckman Coulter, and MaxCyte. The company reports 1-10 employees per firmographic data (though operations include 18+ active integration and channel partnerships), privately held, with no disclosed funding rounds, revenue, or institutional ownership in the available source material.

Short descriptiontext

AsedaSciences operates the 3RnD cloud platform, combining AI-driven machine learning with proprietary high-content cellular, zebrafish, and chromatography screening to predict compound toxicity for pharmaceutical, biotechnology, agricultural chemical, cosmetics, and academic drug discovery customers worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWest Lafayette, United States
HQ citystring
West Lafayette
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
phenotypic screening services, toxicity prediction platform, drug discovery software, non-animal testing methods, compound safety assessment
Industry4 codes
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGADAB
Method Development & Validation (ICH/USP)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYAFACAKAF
Pesticide Residue & Agrochemical Screening Services (Soil/Plant/Water)
Agriculture & Food Production/Agricultural Services (Custom Farming, Agronomy, Veterinary)/Agricultural Testing & Diagnostics Services (Soil, Plant Tissue, Water)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Testing Laboratories and Services54138
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Computational Toxicology Software
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1SaaS Platform Subscriptions
TypeSubscription Recurring
Description

Monthly and annual subscription tiers for the 3RnD platform providing tiered access to compound screening tools, data visualization, and AI-powered analytics. Revenue recurs on a subscription basis with annual discounts available.

2Contract Screening Services
TypeUsage Based
Description

Per-test and project-based screening services using zebrafish models, biomimetic chromatography, and cell-based assays. Revenue generated through individual test fees ranging from $180 to $2,000 depending on assay complexity.

3Software Licensing
TypeOne Time License
Description

Enterprise licensing of SciScore and specialized screening tools for pharmaceutical and biotech clients requiring dedicated deployments or on-premise installations.

4Data and Analytics
TypeData Monetisation
Description

Access to proprietary datasets including GOSTAR database integration and historical compound screening data, provided as premium add-on services to platform subscribers.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details8 tiers
1Free tier for individual researchers to explore basic 3RnD platform functionality
ModelFreemiumBilling cadenceMonthly
Notes

Basic access includes limited compound queries and standard visualization tools with no cost to the user.

2Starter plan for small research teams needing enhanced capabilities
ModelSubscriptionBilling cadenceMonthly
Notes

$99/month provides increased compound query limits, standard visualization features, and email support.

3Academic-focused plan with research-specific tools and reduced pricing
ModelSubscriptionBilling cadenceMonthly
Notes

$199/month offers advanced analytics, unlimited academic publications scoring, and priority support for academic institutions.

4Full commercial access for pharmaceutical and biotech organizations
ModelSubscriptionBilling cadenceMonthly
Notes

$299/month includes complete platform access, enterprise integrations, dedicated support, and commercial usage rights.

5SciScore credit packages for research methodology evaluation
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Academic pricing: 3 credits for $39.99. Commercial pricing: 3 credits for $49.99. Volume discounts available for larger research organizations.

6In vivo zebrafish screening for developmental and acute toxicity assessment
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard zebrafish screen: $629 per compound. Extended endpoint analysis: $1,999 per compound including developmental toxicity and behavioral endpoints.

7Blood-brain barrier permeability and tissue distribution prediction
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Valko Screen (Biomimetic Chromatography): $390-$450 per compound depending on tissue panel size and Turnaround Time requirements.

8Quality control and purity verification for compound libraries
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard QC: $180 per compound. Comprehensive QC with stability profiling: $200 per compound.

GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
13RnD
Description

Cloud-based AI-driven platform that enables scientists to visualize and explore the relationship between chemical structure and biological effects to design safer compounds. Integrates chemistry, biology, and toxicology data with machine learning and elegant visualization tools.

asedasciences.com
+5 more records
Core offering1 text field

AsedaSciences provides multi-parametric phenotypic screening services and a cloud-based AI-driven platform (3RnD) for compound safety assessment. The company combines proprietary high-content cellular screening (SYSTEMETRIC), zebrafish embryo screening (ZBEScreen), and biomimetic chromatography with machine learning algorithms to generate biological fingerprints that predict human and environmental toxicity risk without animal testing. Services and software target pharmaceutical, biotech, agrochemical, cosmetics, and academic drug discovery organizations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 18,000+ research teams actively using the platform across 186 countries
+1 more record
Product overview1 text field

AsedaSciences offers a cloud-based AI-driven platform ecosystem centered on the 3RnD platform, which integrates chemistry, biology, and toxicology data through ML-powered visualization tools. The core 3RnD platform is supported by proprietary screening services including SYSTEMETRIC Cell Health Screen (measuring 12 cellular stress endpoints), ZBEScreen zebrafish screening (16 endpoints), and Biomimetic Chromatography (6 endpoints). The platform features specialized visualization modules including Compound Universe, Zebrafish Universe, and Kinome Universe for comparative compound analysis. Add-on services include SciScore for publication rigor assessment and GOSTAR compound reports for SAR data. The platform is available through tiered subscription plans (Basic/Starter/Academic+/Commercial) and integrates third-party screening and data services from partners including AssayQuant, CellPort Software, and Chemspace.

Product and service7 records
13RnD Platform
CategorySaaS Platform
Description

Cloud-based AI-driven platform integrating chemistry, biology, and toxicology data visualization to help scientists predict toxicity risk and design safer compounds. Available to pharmaceutical, biotech, agrochemical, cosmetics, food safety, and academic research organizations through tiered subscription plans.

2SYSTEMETRIC Cell Health Screen
CategoryScreening Service
Description

Proprietary high-content flow cytometry-based phenotypic screening service measuring 12 parameters of cellular stress across 10 concentrations to generate biological fingerprints for ML-based acute toxicity risk prediction. Used by pharmaceutical and chemical companies for early safety assessment.

3ZBEScreen Zebrafish Screening Service
CategoryScreening Service
Description

Zebrafish embryo screening service measuring 16 organ and behavioral endpoints for developmental and acute neurotoxicity assessment, offered in collaboration with Tanguay Lab at $629-$1,999 per compound. Used by pharmaceutical and chemical companies for in vivo toxicity screening.

4Biomimetic Chromatography Screening (Valko Screen)
CategoryScreening Service
Description

HPLC-based analytical screening service assessing drug properties including lipophilicity, human protein binding, and phospholipid binding as indicators of in vivo distribution and toxicity risk, offered at $390-$450 per compound. Developed in collaboration with Dr. Klara Valko.

5Compound QC
CategoryScreening Service
Description

Quality control screening service measuring compound stability and solubility using HPLC methods at $180-$200 per compound. Supports compound library curation and integrity verification for pharmaceutical and biotech clients.

6SciScore
CategoryResearch Analytics Tool
Description

NLP-based tool that automatically assesses and scores scientific rigor of materials and methods sections in publications to improve research reproducibility. Sold via credit packages ($39.99 academic / $49.99 commercial for 3 credits) to researchers and institutions.

7GOSTAR Compound Reports
CategoryData Product
Description

Downloadable compound annotation reports integrating Excelra's GOSTAR database (10M+ chemical structures) into the 3RnD platform, providing SAR insights and historical compound data for drug discovery researchers.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
1Tanguay Lab
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-05
Description

Research collaboration with Tanguay Lab for zebrafish screening methodology development. Provides expertise in developmental toxicity assessment and assay optimization for the Zebrafish Universe platform.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-10-10
Description

GPCR screening partnership providing access to comprehensive G-protein coupled receptor binding data for off-target toxicity assessment during compound profiling.

3Dr. Klara Valko
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-15
Description

Scientific collaboration with Dr. Klara Valko for development and commercialization of Biomimetic Chromatography technology (Valko Screen) for blood-brain barrier permeability and tissue distribution prediction.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-09-01
Description

Cell line partnership providing authenticated cell lines for screening validation. Ensures reproducibility and quality of cell-based assay results integrated into the platform's toxicity prediction workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-08-20
Description

GOSTAR database integration providing access to 28 million+ curated small molecule records with pharmacological and toxicity data. Enhances platform's training datasets and enables benchmarking against historical compound data.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2023-08-10
Description

Digital marketing partnership for demand generation and lead acquisition activities targeting pharmaceutical and biotech decision-makers in key markets.

7Chayon Laboratories
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-07-15
Description

Regional reseller partnership for South Korea market. Chayon Laboratories serves as authorized distributor providing local sales, customer support, and implementation services for Korean customers.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-06-01
Description

Integration of cell culture management capabilities enabling users to track and manage cell-based assay data within the 3RnD platform. Provides seamless data transfer for improved workflow efficiency.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-10
Description

Integration of KinSight Kinome profiling technology enabling comprehensive kinase activity screening within the platform. Provides quantitativekinase binding data for off-target toxicity prediction.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-04-05
Description

Integration providing access to 13 billion+ virtual compounds for computational screening. Enables users to explore extensive chemical space and perform virtual screening against the company's proprietary toxicity models.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-03-20
Description

AI-driven disease research integration providing transcriptomic and proteomic data to enhance compound mechanism-of-action predictions within the 3RnD platform. Enables correlation of gene expression changes with toxicity endpoints.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-02-14
Description

Partnership for compound screening and management services enabling seamless data flow between Simplicis screening workflows and 3RnD platform analysis tools for streamlined drug discovery processes.

13Frontier Scientific
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-02-01
Description

Compound management services partnership providing sample handling, storage, and logistics for client compounds. Ensures integrity and traceability of materials throughout screening workflows.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2023-01-20
Description

Compound library partnership providing reference compounds and screening standards for assay validation. Enables access to curated chemical libraries for quality control and method development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-01-15
Description

Integration partnership enabling Human-on-a-Chip organ system data within the 3RnD platform. Allows users to access multi-organchip toxicity data alongside traditional screening results for comprehensive safety assessment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AsedaSciences

Computational Toxicology Softwareasedasciences.com

AsedaSciences operates the 3RnD cloud platform, combining AI-driven machine learning with proprietary high-content cellular, zebrafish, and chromatography screening to predict compound toxicity for pharmaceutical, biotechnology, agricultural chemical, cosmetics, and academic drug discovery customers worldwide.

What AsedaSciences does

AsedaSciences operates the 3RnD platform, a cloud-based, AI-driven ecosystem that combines machine learning with proprietary high-content cellular screening to predict human toxicity risk and support the design of safer chemical and pharmaceutical compounds. The platform is built around the generation of standardized biological fingerprints using SYSTEMETRIC flow-cytometry-based multiparametric screens (12 cellular stress parameters across 10 concentrations), with proprietary ML algorithms comparing new compound fingerprints against a library of 3,000+ historical fingerprints to generate a Cell Health Index risk score. Native integration with 3RnD also covers complementary screening modalities including ZBEScreen zebrafish screening (16 organ and behavioral endpoints via partnership with Tanguay Lab), Biomimetic Chromatography (Valko Screen, 6 endpoints developed with Dr. Klara Valko), compound QC, and a Kinome profiling module; visualization layers include Compound Universe, Zebrafish Universe, and Kinome Universe, with add-on tools such as the SciScore NLP engine (scoring research rigor across 2.2M+ publications) and GOSTAR compound reports from Excelra.

The company monetizes through four streams: SaaS subscriptions to the 3RnD platform on tiered monthly plans ranging from a free entry tier through a $299/month commercial tier; pay-as-you-go contract screening services priced $180-$2,000 per test depending on assay complexity; enterprise software licensing for SciScore and specialized tools; and premium access to proprietary datasets including the 3,000+ compound biological fingerprint database. Go-to-market is hybrid: a product-led freemium motion at the individual researcher level, direct enterprise field sales targeting pharma and biotech for full-service screening contracts, and regional channel partners (e.g., Chayon Laboratories for South Korea). Customer segments span pharmaceutical and biotechnology companies (primary), agricultural chemicals, industrial chemicals, cosmetics, food safety, and academic drug discovery groups across 186 countries.

The company is incorporated as AsedaSciences AG in Schindellegi, Switzerland (global headquarters) and AsedaSciences Inc. in West Lafayette, Indiana (US operations and laboratory facilities). Operative leadership is led by co-founder and CEO Brad Calvin, who previously held executive roles at Abbott, Digene, Beckman Coulter, and MaxCyte. The company reports 1-10 employees per firmographic data (though operations include 18+ active integration and channel partnerships), privately held, with no disclosed funding rounds, revenue, or institutional ownership in the available source material.

AsedaSciences firmographics

Firmographics
Name
AsedaSciences
Legal name
AsedaSciences AG
Website
https://asedasciences.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
AsedaSciences operates the 3RnD cloud platform, combining AI-driven machine learning with proprietary high-content cellular, zebrafish, and chromatography screening to predict compound toxicity for pharmaceutical, biotechnology, agricultural chemical, cosmetics, and academic drug discovery customers worldwide.
Ownership category
akta.pro rank

AsedaSciences industry classification

Industry
Product category
Computational Toxicology Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Testing Laboratories and Services (54138)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAFAJ
In Vitro Toxicology (Cell-based/Organ-on-chip)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGADAB
Method Development & Validation (ICH/USP)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYAFACAKAF
Pesticide Residue & Agrochemical Screening Services (Soil/Plant/Water)
Agriculture & Food Production/Agricultural Services (Custom Farming, Agronomy, Veterinary)/Agricultural Testing & Diagnostics Services (Soil, Plant Tissue, Water)

Keywords

  • Phenotypic screening services
  • Toxicity prediction platform
  • Drug discovery software
  • Non-animal testing methods
  • Compound safety assessment

Where AsedaSciences is headquartered

Location

Headquarters

HQ city
West Lafayette
HQ country
United States
HQ region
North America

Offices2 records

Markets served

AsedaSciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. SaaS Platform Subscriptions: Monthly and annual subscription tiers for the 3RnD platform providing tiered access to compound screening tools, data visualization, and AI-powered analytics. Revenue recurs on a subscription basis with annual discounts available.
  2. Contract Screening Services: Per-test and project-based screening services using zebrafish models, biomimetic chromatography, and cell-based assays. Revenue generated through individual test fees ranging from $180 to $2,000 depending on assay complexity.
  3. Software Licensing: Enterprise licensing of SciScore and specialized screening tools for pharmaceutical and biotech clients requiring dedicated deployments or on-premise installations.
  4. Data and Analytics: Access to proprietary datasets including GOSTAR database integration and historical compound screening data, provided as premium add-on services to platform subscribers.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree tier for individual researchers to explore basic 3RnD platform functionality
SubscriptionMonthlyStarter plan for small research teams needing enhanced capabilities
SubscriptionMonthlyAcademic-focused plan with research-specific tools and reduced pricing
SubscriptionMonthlyFull commercial access for pharmaceutical and biotech organizations
Unit PricingPay-as-you-goSciScore credit packages for research methodology evaluation
Unit PricingPay-as-you-goIn vivo zebrafish screening for developmental and acute toxicity assessment
Unit PricingPay-as-you-goBlood-brain barrier permeability and tissue distribution prediction
Unit PricingPay-as-you-goQuality control and purity verification for compound libraries

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

AsedaSciences product offering

Product offering

Core offering

AsedaSciences provides multi-parametric phenotypic screening services and a cloud-based AI-driven platform (3RnD) for compound safety assessment. The company combines proprietary high-content cellular screening (SYSTEMETRIC), zebrafish embryo screening (ZBEScreen), and biomimetic chromatography with machine learning algorithms to generate biological fingerprints that predict human and environmental toxicity risk without animal testing. Services and software target pharmaceutical, biotech, agrochemical, cosmetics, and academic drug discovery organizations.

Product overview

AsedaSciences offers a cloud-based AI-driven platform ecosystem centered on the 3RnD platform, which integrates chemistry, biology, and toxicology data through ML-powered visualization tools. The core 3RnD platform is supported by proprietary screening services including SYSTEMETRIC Cell Health Screen (measuring 12 cellular stress endpoints), ZBEScreen zebrafish screening (16 endpoints), and Biomimetic Chromatography (6 endpoints). The platform features specialized visualization modules including Compound Universe, Zebrafish Universe, and Kinome Universe for comparative compound analysis. Add-on services include SciScore for publication rigor assessment and GOSTAR compound reports for SAR data. The platform is available through tiered subscription plans (Basic/Starter/Academic+/Commercial) and integrates third-party screening and data services from partners including AssayQuant, CellPort Software, and Chemspace.

Differentiator

Problem solved

Functional benefit

Brands

  • 3RnD: Cloud-based AI-driven platform that enables scientists to visualize and explore the relationship between chemical structure and biological effects to design safer compounds. Integrates chemistry, biology, and toxicology data with machine learning and elegant visualization tools.
  • SYSTEMETRIC
  • ZBEScreen
  • Compound Universe
  • SciScore
  • NAM Central

Products and services

  • 3RnD Platform Cloud-based AI-driven platform integrating chemistry, biology, and toxicology data visualization to help scientists predict toxicity risk and design safer compounds. Available to pharmaceutical, biotech, agrochemical, cosmetics, food safety, and academic research organizations through tiered subscription plans.
  • SYSTEMETRIC Cell Health Screen Proprietary high-content flow cytometry-based phenotypic screening service measuring 12 parameters of cellular stress across 10 concentrations to generate biological fingerprints for ML-based acute toxicity risk prediction. Used by pharmaceutical and chemical companies for early safety assessment.
  • ZBEScreen Zebrafish Screening Service Zebrafish embryo screening service measuring 16 organ and behavioral endpoints for developmental and acute neurotoxicity assessment, offered in collaboration with Tanguay Lab at $629-$1,999 per compound. Used by pharmaceutical and chemical companies for in vivo toxicity screening.
  • Biomimetic Chromatography Screening (Valko Screen) HPLC-based analytical screening service assessing drug properties including lipophilicity, human protein binding, and phospholipid binding as indicators of in vivo distribution and toxicity risk, offered at $390-$450 per compound. Developed in collaboration with Dr. Klara Valko.
  • Compound QC Quality control screening service measuring compound stability and solubility using HPLC methods at $180-$200 per compound. Supports compound library curation and integrity verification for pharmaceutical and biotech clients.
  • SciScore NLP-based tool that automatically assesses and scores scientific rigor of materials and methods sections in publications to improve research reproducibility. Sold via credit packages ($39.99 academic / $49.99 commercial for 3 credits) to researchers and institutions.
  • GOSTAR Compound Reports Downloadable compound annotation reports integrating Excelra's GOSTAR database (10M+ chemical structures) into the 3RnD platform, providing SAR insights and historical compound data for drug discovery researchers.

Quantifiable outcome

  • 18,000+ research teams actively using the platform across 186 countries
  • +1 more outcomes

Companies that use AsedaSciences

Customer profile

Segments7 records

Ideal customer profiles4 records

AsedaSciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature6 records

AsedaSciences partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, major, minor and regional.

  • Tanguay LabcoreStrategic or Co-development Partner · 5 November 2023Research collaboration with Tanguay Lab for zebrafish screening methodology development. Provides expertise in developmental toxicity assessment and assay optimization for the Zebrafish Universe platform.
  • EuroscreenFastmajorTechnology or Integration · 10 October 2023GPCR screening partnership providing access to comprehensive G-protein coupled receptor binding data for off-target toxicity assessment during compound profiling.
  • Dr. Klara ValkocoreStrategic or Co-development Partner · 15 September 2023Scientific collaboration with Dr. Klara Valko for development and commercialization of Biomimetic Chromatography technology (Valko Screen) for blood-brain barrier permeability and tissue distribution prediction.
  • CytionmajorTechnology or Integration · 1 September 2023Cell line partnership providing authenticated cell lines for screening validation. Ensures reproducibility and quality of cell-based assay results integrated into the platform's toxicity prediction workflows.
  • Excelra (GOSTAR)coreTechnology or Integration · 20 August 2023GOSTAR database integration providing access to 28 million+ curated small molecule records with pharmacological and toxicity data. Enhances platform's training datasets and enables benchmarking against historical compound data.
  • Supreme OptimizationminorGTM or Marketing Partner · 10 August 2023Digital marketing partnership for demand generation and lead acquisition activities targeting pharmaceutical and biotech decision-makers in key markets.
  • Chayon LaboratoriesregionalChannel Partner/ Reseller/ Distributor · 15 July 2023Regional reseller partnership for South Korea market. Chayon Laboratories serves as authorized distributor providing local sales, customer support, and implementation services for Korean customers.
  • CellPort SoftwaremajorTechnology or Integration · 1 June 2023Integration of cell culture management capabilities enabling users to track and manage cell-based assay data within the 3RnD platform. Provides seamless data transfer for improved workflow efficiency.
  • AssayQuantcoreTechnology or Integration · 10 May 2023Integration of KinSight Kinome profiling technology enabling comprehensive kinase activity screening within the platform. Provides quantitativekinase binding data for off-target toxicity prediction.
  • ChemspacecoreTechnology or Integration · 5 April 2023Integration providing access to 13 billion+ virtual compounds for computational screening. Enables users to explore extensive chemical space and perform virtual screening against the company's proprietary toxicity models.
  • EuretoscoreTechnology or Integration · 20 March 2023AI-driven disease research integration providing transcriptomic and proteomic data to enhance compound mechanism-of-action predictions within the 3RnD platform. Enables correlation of gene expression changes with toxicity endpoints.
  • SimplicismajorTechnology or Integration · 14 February 2023Partnership for compound screening and management services enabling seamless data flow between Simplicis screening workflows and 3RnD platform analysis tools for streamlined drug discovery processes.
  • Frontier ScientificmajorTechnology or Integration · 1 February 2023Compound management services partnership providing sample handling, storage, and logistics for client compounds. Ensures integrity and traceability of materials throughout screening workflows.
  • Cayman ChemicalmajorTechnology or Integration · 20 January 2023Compound library partnership providing reference compounds and screening standards for assay validation. Enables access to curated chemical libraries for quality control and method development.
  • HesperoscoreTechnology or Integration · 15 January 2023Integration partnership enabling Human-on-a-Chip organ system data within the 3RnD platform. Allows users to access multi-organchip toxicity data alongside traditional screening results for comprehensive safety assessment.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

AsedaSciences competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

AsedaSciences social profiles

Digital presence

AsedaSciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AsedaSciences leadership team

Management profile

Number of profiles

Profiles1 record

AsedaSciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AsedaSciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AsedaSciences

What does AsedaSciences do?

AsedaSciences provides multi-parametric phenotypic screening services and a cloud-based AI-driven platform (3RnD) for compound safety assessment. The company combines proprietary high-content cellular screening (SYSTEMETRIC), zebrafish embryo screening (ZBEScreen), and biomimetic chromatography with machine learning algorithms to generate biological fingerprints that predict human and environmental toxicity risk without animal testing. Services and software target pharmaceutical, biotech, agrochemical, cosmetics, and academic drug discovery organizations.

Is AsedaSciences a public or private company?

AsedaSciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was AsedaSciences founded?

AsedaSciences was founded in 2012. It employs 1 to 10 people.

Where is AsedaSciences based?

AsedaSciences is headquartered in West Lafayette, United States, in the North America region.

How does AsedaSciences make money?

Four revenue lines are on record. SaaS Platform Subscriptions are the primary driver. The others are contract Screening Services, software Licensing and data and Analytics.

Does AsedaSciences have an API?

No public API is recorded for AsedaSciences.

What industry is AsedaSciences in?

AsedaSciences's product category is Computational Toxicology Software. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip), with a secondary code of HLAGADAB, Method Development & Validation (ICH/USP). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireAsedaSciences® and eMolecules Partner to Integrate Professional Compound Management Services into the 3RnD® PlatformAsedaSciences and eMolecules announced a strategic agreement to integrate eMolecules' Frontier Scientific compound management services into the 3RnD platform. The partnership covers storage, preparation, aliquoting, quality control, and inventory management, aiming to improve data quality and reproducibility in chemical R&D.EIN PresswireAsedaSciences and Biobide Announce Strategic Agreement to Integrate Aquatic Toxicity Testing Services into 3RnD PlatformAsedaSciences and Biobide announced a strategic agreement to integrate Biobide's aquatic toxicity screening services into the 3RnD platform. The partnership allows users to order studies, consolidate data, and compare results against a growing reference library. It aims to streamline toxicity assessment for chemical developers.EIN PresswireAsedaSciences and EuroscreenFast Partner to add GPCR Screening of Chemicals into the 3RnD Toxicity Risk EcosystemAsedaSciences and EuroscreenFast announced a commercial sales and marketing agreement to integrate EuroscreenFast's GPCR screening capabilities into AsedaSciences' 3RnD toxicity risk assessment platform. The partnership will provide customers access to over 1,000 functional assays covering more than 560 GPCR and related targets, strengthening mechanistic measurement of receptor-mediated toxicity risk in chemical and pharmaceutical development. The collaboration aims to improve safety prediction, reduce late-stage drug attrition, and accelerate the design of safer compounds through combined AI-driven data integration and specialized GPCR expertise.EIN PresswireCytion and AsedaSciences Announce Partnership to support Early Safety Prediction with Target Driven Cell Model SelectionCytion and AsedaSciences announced an exclusive partnership making Cytion the sole cell line partner for AsedaSciences' 3RnD cloud platform, combining authenticated human cell models with AI-driven phenotypic screening to help researchers identify compound safety and toxicity risks earlier in drug development. The collaboration will roll out an integrated target-to-cell workflow allowing scientists to search cell lines by biological target and proceed directly to ordering, streamlining experimental setup. The partnership will be implemented in phases with pilot users to refine the target-to-cell discovery experience.Business & FinancialAsedasciences® Announces The Launch Of Zebrafish Screening Service In Collaboration With The Tanguay LabAsedaSciences launched a zebrafish screening service in collaboration with the Tanguay Lab, offering early toxicity assessment for chemical and drug candidates. The ZBEScreenTM provides automated imaging and behavioral assessments, enabling screening of over 800 compounds at a fraction of traditional animal testing costs.GlobeNewswireAsedaSciences, Inc. Wins Mid-Atlantic Bio Angels 1st Pitch Life Science Pennsylvania CompetitionAsedaSciences, a biotechnology firm, won Best in Show at Mid-Atlantic Bio Angels' Philadelphia 1st Pitch Life Science event on March 26, 2015. The company's technology enables high-throughput phenotypic cell screening to de-risk drug lead compounds. The event provides constructive investor feedback to refine pitches.